GLP-1 Medications and Fertility: What the Research Shows

Millions of women and men of reproductive age are now using GLP-1 receptor agonists (GLP-1 RAs) for weight management and metabolic health. As prescriptions for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to climb, a critical question has emerged: how do these medications affect fertility, and is it safe to use them when planning a pregnancy?

The answers are more nuanced — and in many ways more encouraging — than initially expected. A growing body of research from 2024 and 2025 suggests that GLP-1 RAs may actively improve reproductive outcomes for certain populations, particularly women with PCOS or obesity. At the same time, clear guidelines around discontinuation before conception are essential for anyone planning a pregnancy.

Evidence: "GLP-1 receptor agonists improved menstrual regularity, decreased body weight, increased sex hormone-binding globulin levels, and lowered free testosterone in overweight and obese women with PCOS." — Oliveira et al. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health. 2025. PubMed

GLP-1 Medications and Female Fertility

How These Medications Affect the Reproductive System

GLP-1 receptors are not limited to the pancreas and gut. Research has confirmed their presence in multiple reproductive tissues — including the ovaries, endometrium, and fallopian tubes. This widespread expression indicates GLP-1 RAs can directly influence reproductive biology beyond their weight-loss effects.

For women with obesity or PCOS — conditions that frequently impair fertility — the benefits operate through several overlapping mechanisms:

• Improved insulin sensitivity reduces hyperinsulinemia, which drives androgen overproduction in the ovaries
• Weight reduction lowers circulating estrogens stored in adipose tissue, restoring ovulatory cycles
• Direct ovarian signaling through GLP-1 receptors modulates granulosa cell function and follicular development

Evidence: "GLP-1R signaling may directly affect ovarian physiology, influencing granulosa cell proliferation, survival pathways, and steroidogenic production, in addition to its systemic metabolic effects." — Systematic Review on GLP-1 Receptor Agonists in Reproductive Health. PMC. 2025. PMC

Semaglutide and Pregnancy Rates in PCOS

A 2025 randomized controlled trial enrolled 100 overweight or obese women with PCOS, comparing metformin monotherapy versus combined metformin plus semaglutide (1 mg weekly for 16 weeks). The results were striking:

Outcome	Metformin Only	Metformin + Semaglutide
Menstrual cycle recovery at week 16	42.3%	72.5%
Natural pregnancy rate during follow-up	15%	35%
Total pregnancies at 24-week follow-up	32.5%	50.0%

Evidence: "Combination therapy with semaglutide and metformin significantly reduced body weight, improved insulin resistance, alleviated menstrual irregularities, and increased natural pregnancy rates in overweight/obese women with PCOS." — Ma et al. Frontiers in Endocrinology. 2025. PMC

GLP-1 Medications and IVF Outcomes

For women undergoing in vitro fertilization, early data suggest meaningful benefits. Pilot studies using liraglutide prior to IVF in PCOS patients showed clinical pregnancy rates substantially higher than controls — and investigators found the improvement went beyond what weight loss alone could explain.

The endometrium expresses GLP-1 receptors, and researchers now hypothesize that GLP-1 RAs may enhance implantation potential through direct molecular signaling, not solely via metabolic improvement.

Evidence: "The pregnancy rate after embryo transfer was significantly higher in the combination [GLP-1 RA] group (85.7%) than in the metformin alone group (28.6%), suggesting effects beyond weight reduction alone." — The Hidden Impact of GLP-1 Receptor Agonists on Endometrial Receptivity. PMC. 2025. PMC

GLP-1 Medications and Male Fertility

Male reproductive health has received less attention in this context, but emerging data is largely reassuring — and for men with metabolic issues, potentially beneficial.

Testosterone and Hormonal Improvements

Obesity-related functional hypogonadism — low testosterone driven by excess adipose tissue converting testosterone to estrogen — is common in men with significant excess weight. GLP-1 RAs can meaningfully reverse this process through fat reduction.

A 2025 systematic review analyzing GLP-1 RA effects on male reproductive hormones found consistent improvements:

Parameter	Direction of Change	Evidence Quality
Total testosterone	Significant increase	Moderate–high
Sex hormone-binding globulin	Increase	Moderate
Estradiol	Decrease	Moderate
Sperm count	Improvement	Low–moderate
Sperm motility	Improvement	Low–moderate

Evidence: "Treatment with GLP-1RAs produced a significant increase in total serum testosterone in men with obesity, type 2 diabetes, or functional hypogonadism." — Systematic review, glucagon-like peptide-1 receptor agonists on male reproductive hormones. PubMed. 2025. PubMed

A separate 2024 randomized, double-blind, placebo-controlled crossover study in healthy men found no detrimental effects from four weeks of dulaglutide treatment on sexual desire, hypothalamic-pituitary-gonadal axis hormones, or sperm parameters.

Evidence: "No evidence of negative impacts of a four-week treatment with dulaglutide was found on sexual desire, hypothalamic-pituitary-gonadal hormones, or sperm parameters in healthy men." — Giorgetti et al. eBioMedicine (Lancet). 2024. eBioMedicine

Safety in Pregnancy: Critical Guidance

Despite the reproductive benefits observed in fertility-seeking populations, all current clinical guidelines advise stopping GLP-1 RAs before attempting conception. This recommendation is grounded in three concerns:

1. Animal Safety Data

Preclinical studies in rodents and rabbits demonstrated fetal harm at doses exceeding clinical exposure levels. Regulatory agencies treat such findings as grounds for caution until robust human developmental outcome data accumulate.

2. Drug Half-Life and Washout Period

Semaglutide's half-life of approximately 7 days means it takes roughly 5 weeks to clear from the body. Current guidance:

Medication	Half-life	Recommended Washout Before Conception
Semaglutide (Ozempic/Wegovy)	~7 days	At least 2 months
Tirzepatide (Mounjaro/Zepbound)	~5 days	At least 1 month
Liraglutide (Victoza/Saxenda)	~13 hours	At least 2 weeks

3. Early Pregnancy Exposure Data

For women who inadvertently conceived while on GLP-1 therapy — before knowing they were pregnant — available human data is largely reassuring.

A 2024 multicenter observational cohort study from six Teratology Information Services across Europe and North America tracked pregnancies with first-trimester GLP-1 RA exposure and found no significant increase in congenital anomalies or pregnancy loss compared to controls.

Evidence: "Human data suggest that inadvertent early pregnancy exposure to GLP-1 receptor agonists does not significantly increase teratogenic risk; however, all guidelines advise discontinuation before planned conception." — Dao et al. Use of GLP-1 receptor agonists in early pregnancy and reproductive safety. PMC. 2024. PMC

A subsequent 2025 analysis of pregnancy outcomes after semaglutide exposure reached similar conclusions, while emphasizing the need for ongoing post-marketing surveillance as use in reproductive-age populations expands.

Evidence: "Current evidence does not indicate a significantly elevated risk of adverse pregnancy outcomes following semaglutide exposure, though long-term developmental follow-up data remain limited." — Pregnancy Outcomes After Semaglutide Exposure. PMC. 2025. PMC

Practical Recommendations for Those Planning a Pregnancy

For Women With PCOS or Obesity

The evidence is strongest in this group. GLP-1 RAs can serve as effective bridge therapy — improving hormonal profiles, restoring ovulatory cycles, and enhancing IVF outcomes — before discontinuing for conception. Discuss a specific timeline with your reproductive endocrinologist.

For Women Without PCOS or Metabolic Conditions

Research in this subgroup remains sparse. Weight loss from GLP-1 RAs may still restore ovulatory function in women with obesity, but the direct fertility effects outside a PCOS context require further study. A cautious, individualized approach is appropriate.

For Men

Current evidence suggests GLP-1 RAs either improve or have neutral effects on reproductive hormones and sperm parameters. No washout period is currently recommended for men, though long-term controlled data remain limited. Men concerned about fertility should consult a urologist or reproductive specialist.

Key Steps Before Attempting Conception

1. Discuss your pregnancy timeline with your prescribing physician at least 3–6 months in advance
2. Complete the recommended washout period for your specific medication
3. If weight regain is a concern after stopping, discuss alternative strategies (dietary modification, supervised exercise, or low-risk pharmacotherapy compatible with early pregnancy)
4. Track menstrual cycle regularity after discontinuation — restoration of regular cycles is a positive sign of reproductive function

For further reading, see our guides on GLP-1 medications and PCOS and weight regain after stopping GLP-1 medications.

Key Takeaways

GLP-1 receptor agonists occupy a genuinely promising position in reproductive medicine, particularly for women with PCOS and obesity. The growing body of research from 2024 and 2025 supports the following conclusions:

• Women with PCOS and obesity see significantly improved menstrual regularity, hormonal profiles, and pregnancy rates — both natural and IVF-assisted
• Endometrial and ovarian effects appear to extend beyond weight loss alone, suggesting direct reproductive signaling through GLP-1 receptors
• Early pregnancy exposure has not been shown to significantly increase congenital risk in available human cohort data, though animal data urge caution
• Planned discontinuation of at least 2 months before conception remains the standard of care for semaglutide users
• Men can expect hormonal improvements with no confirmed detrimental effects on sperm quality

As with all emerging areas of medicine, the pace of research is encouraging but gaps remain real. Anyone navigating GLP-1 therapy alongside fertility planning should work closely with both their prescribing physician and a reproductive endocrinologist.

---

References

1. Ma X, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Frontiers in Endocrinology. 2025. PMC

2. Dao B, et al. Use of GLP-1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. PMC. 2024. PMC

3. Authors et al. The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation. PMC. 2025. PMC

4. Authors et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. PubMed. 2025. PubMed

5. Cavoretto PI, et al. GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence. PMC. 2025. PMC

6. Giorgetti R, et al. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine (Lancet). 2024. eBioMedicine

7. Authors et al. Pregnancy Outcomes After Semaglutide Exposure. PMC. 2025. PMC

8. Authors et al. A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms. PMC. 2025. PMC

---

Last updated: 2026-04-17 Medical review: Dr. James Chen, MD, PhD, FACE